Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype

The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the...

Full description

Bibliographic Details
Main Authors: Marika Comegna, Vito Terlizzi, Donatello Salvatore, Carmela Colangelo, Antonella Miriam Di Lullo, Immacolata Zollo, Giovanni Taccetti, Giuseppe Castaldo, Felice Amato
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Antibiotics
Subjects:
theratyping
cystic fibrosis
functional characterization
personalized medicine
CFTR
rare mutation
Online Access:https://www.mdpi.com/2079-6382/10/7/828

Internet

https://www.mdpi.com/2079-6382/10/7/828

Similar Items